These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17785018)

  • 41. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.
    Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J
    AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241
    [No Abstract]   [Full Text] [Related]  

  • 42. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
    Young J; Glass TR; Bernasconi E; Rickenbach M; Furrer H; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC;
    J Clin Epidemiol; 2009 Jun; 62(6):632-41. PubMed ID: 19108985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug interactions. Atazanavir and acid-reducing agents.
    TreatmentUpdate; 2006; 18(3):4. PubMed ID: 17209238
    [No Abstract]   [Full Text] [Related]  

  • 44. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis.
    Inagaki I; Adachi M; Ito H; Yasuda M; Tsurumi H; Deguchi T; Seishima M
    Urol Int; 2015; 94(1):121-4. PubMed ID: 24334974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA notifications. Alternative dosing regimen for atazanavir is approved.
    AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
    [No Abstract]   [Full Text] [Related]  

  • 48. FDA notifications. Revised atazanavir package insert.
    AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
    [No Abstract]   [Full Text] [Related]  

  • 49. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.
    Brewster UC; Perazella MA
    Am J Kidney Dis; 2004 Nov; 44(5):e81-4. PubMed ID: 15492941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypermenorrhea associated with ritonavir.
    Nielsen H
    Lancet; 1999 Mar; 353(9155):811-2. PubMed ID: 10459969
    [No Abstract]   [Full Text] [Related]  

  • 52. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient.
    Moriyama Y; Minamidate Y; Yasuda M; Ehara H; Kikuchi M; Tsuchiya T; Deguchi T; Tsurumi H
    Urol Res; 2008 Oct; 36(5):275-7. PubMed ID: 18633605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
    Fleischbein E; O'Brien J; Martelino R; Fenstersheib M
    AIDS; 2008 Nov; 22(17):2404-5. PubMed ID: 18981785
    [No Abstract]   [Full Text] [Related]  

  • 54. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atazanavir in plasma-exchange treatment.
    Attema-de Jonge ME; Burger DM; Franssen EJ; Brinkman K
    AIDS; 2007 Apr; 21(7):884-5. PubMed ID: 17415050
    [No Abstract]   [Full Text] [Related]  

  • 56. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New pediatric dosing recommendations for atazanavir.
    AIDS Patient Care STDS; 2008 Apr; 22(4):347. PubMed ID: 18434948
    [No Abstract]   [Full Text] [Related]  

  • 60. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.